Last reviewed · How we verify
Quadrivalent Influenza mRNA Vaccine MRT5421 — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Quadrivalent Influenza mRNA Vaccine MRT5421 (Quadrivalent Influenza mRNA Vaccine MRT5421) — Sanofi Pasteur, a Sanofi Company.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Quadrivalent Influenza mRNA Vaccine MRT5421 TARGET | Quadrivalent Influenza mRNA Vaccine MRT5421 | Sanofi Pasteur, a Sanofi Company | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Quadrivalent Influenza mRNA Vaccine MRT5421 CI watch — RSS
- Quadrivalent Influenza mRNA Vaccine MRT5421 CI watch — Atom
- Quadrivalent Influenza mRNA Vaccine MRT5421 CI watch — JSON
- Quadrivalent Influenza mRNA Vaccine MRT5421 alone — RSS
Cite this brief
Drug Landscape (2026). Quadrivalent Influenza mRNA Vaccine MRT5421 — Competitive Intelligence Brief. https://druglandscape.com/ci/quadrivalent-influenza-mrna-vaccine-mrt5421. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab